CA2371114A1 - Death domain containing receptors - Google Patents

Death domain containing receptors Download PDF

Info

Publication number
CA2371114A1
CA2371114A1 CA002371114A CA2371114A CA2371114A1 CA 2371114 A1 CA2371114 A1 CA 2371114A1 CA 002371114 A CA002371114 A CA 002371114A CA 2371114 A CA2371114 A CA 2371114A CA 2371114 A1 CA2371114 A1 CA 2371114A1
Authority
CA
Canada
Prior art keywords
polypeptide
seq
amino acid
antibody
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002371114A
Other languages
English (en)
French (fr)
Inventor
Guo-Liang Yu
Jian Ni
Reiner L. Gentz
Patrick J. Dillon
Vishva M. Dixit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
University of Michigan
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2371114A1 publication Critical patent/CA2371114A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002371114A 1999-04-22 2000-04-21 Death domain containing receptors Abandoned CA2371114A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13048899P 1999-04-22 1999-04-22
US60/130,488 1999-04-22
US13674199P 1999-05-28 1999-05-28
US60/136,741 1999-05-28
PCT/US2000/010741 WO2000064465A1 (en) 1999-04-22 2000-04-21 Death domain containing receptors

Publications (1)

Publication Number Publication Date
CA2371114A1 true CA2371114A1 (en) 2000-11-02

Family

ID=26828526

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002371114A Abandoned CA2371114A1 (en) 1999-04-22 2000-04-21 Death domain containing receptors

Country Status (5)

Country Link
EP (1) EP1178815A4 (de)
JP (1) JP2003522118A (de)
AU (1) AU4478200A (de)
CA (1) CA2371114A1 (de)
WO (1) WO2000064465A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469144B1 (en) 1996-04-01 2002-10-22 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
JP2003514031A (ja) * 1999-11-19 2003-04-15 トーマス ブイ． ティットル， Ｔｒ３特異的結合剤およびその使用のための方法
US6994976B1 (en) 1999-11-19 2006-02-07 Tittle Thomas V Tr3-specific binding agents and methods for their use
WO2003013581A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Agonists and antagonists of genceptin for the treatment of metabolic disorders
EP1361433A3 (de) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Verfahren zur erkennung die therapeutisches Wirkung TNF
DK1667730T3 (da) * 2003-08-20 2013-09-23 Univ Miami Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom
CA2590461A1 (en) * 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
ES2611307T3 (es) 2005-08-30 2017-05-08 University Of Miami Inmunomodulación de agonistas, antagonistas e inmunotoxinas del receptor del factor de necrosis tumoral 25 (TNFR25)
EP2462165B1 (de) 2009-08-03 2016-05-11 University of Miami Verfahren zur in-vivo-expansion regulatorischer t-zellen
WO2012117067A1 (en) 2011-03-01 2012-09-07 Novo Nordisk A/S Antagonistic dr3 ligands
JP2016504045A (ja) 2013-01-09 2016-02-12 ザ ユニバーシティー オブ マイアミＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉａｍｉ ＴＬ１Ａ−Ｉｇ融合タンパク質を用いる制御性Ｔ細胞の制御のための組成物及び方法
EP3126396A4 (de) * 2014-04-04 2017-09-06 Kyowa Hakko Kirin Co., Ltd. Antagonistische anti-death-rezeptor 3 (dr3)-antikörper mit verringerter agonistischer aktivität

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
WO1997033904A1 (en) * 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US6469144B1 (en) * 1996-04-01 2002-10-22 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
PT1012274E (pt) * 1997-01-28 2007-08-14 Craig A Rosen Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)

Also Published As

Publication number Publication date
EP1178815A1 (de) 2002-02-13
AU4478200A (en) 2000-11-10
WO2000064465A1 (en) 2000-11-02
JP2003522118A (ja) 2003-07-22
EP1178815A4 (de) 2003-02-05

Similar Documents

Publication Publication Date Title
US8105589B2 (en) Use of DR3 antibodies in the treatment of inflammatory disease
US6902910B2 (en) Death domain containing receptor 4
US7186800B1 (en) Tumor necrosis factor 6α and 6β
US7511017B2 (en) Methods of treatment with TNFR5
US6919078B2 (en) Antibodies to human tumor necrosis factor receptor TR9
US7452538B2 (en) Death domain containing receptor 4 antibodies and methods
US7476384B2 (en) Death domain containing receptor 4 antibody and methods
US7709218B2 (en) Tumor necrosis factor receptors 6α and 6β
US20060234285A1 (en) Tumor Necrosis Factor Receptors 6 Alpha & 6 Beta
US20050282217A1 (en) Human tumor necrosis factor receptor TR10
CA2371114A1 (en) Death domain containing receptors
WO2000067793A9 (en) Death domain containing receptor 4
US6713061B1 (en) Death domain containing receptors
EP1159286A1 (de) Tumornekrosefaktor-rezeptoren 6 alpha und 6 beta
EP1191940A1 (de) Tumornekrosefaktor rezeptor 5
EP1171579A1 (de) Humaner tumormekrosefaktorrezeptor tr9
US20020098163A1 (en) Human tumor necrosis factor receptors TR21 and TR22
CA2420593A1 (en) Tumor necrosis factor receptors 6.alpha. and 6.beta.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead